Intervention

CDR132L

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting2

Common conditions4

Lead sponsors shown2

Clinical trials

5 shown

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular HypertrophyNCT06979375 · 2025-06-30

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular HypertrophyNCT06979362 · 2025-06-27

Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac HypertrophyNCT05953831 · 2024-04-30

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial InfarctionNCT05350969 · 2022-07-11

Clinical Study to Assess Safety, PK and PD Parameters of CDR132LNCT04045405 · 2019-06-21

Common conditions

Heart Failure3 Heart Failure With Preserved Ejection Fraction1 Heart Failure, Left Sided1 Myocardial Infarction, Acute1

Leading sponsors

Cardior Pharmaceuticals GmbH3 Novo Nordisk A/S2

Trial status mix

COMPLETED2

RECRUITING2

WITHDRAWN1

Phase mix

PHASE24

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.